Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News

Table of Contents

Highlights

  • Highlights
    Highlights of This Issue
    Clin Cancer Res March 15 2017 23 (6) 1363-1363;

CCR Translations

  • CCR Translations
    Predicting MEK Inhibitor Response in Lung Cancer: A Proper Signature Is Required
    Yaohua Xue and Piro Lito
    Clin Cancer Res March 15 2017 23 (6) 1365-1367; DOI:10.1158/1078-0432.CCR-16-2576

CCR Perspectives in Regulatory Science and Policy

  • CCR Perspectives in Regulatory Science and Policy
    An FDA Perspective on the Regulatory Implications of Complex Signatures to Predict Response to Targeted Therapies
    Julia A. Beaver, Abraham Tzou, Gideon M. Blumenthal, Amy E. McKee, Geoffrey Kim, Richard Pazdur and Reena Philip
    Clin Cancer Res March 15 2017 23 (6) 1368-1372; DOI:10.1158/1078-0432.CCR-16-1098

Molecular Pathways

  • Molecular Pathways
    Molecular Pathways: Mucins and Drug Delivery in Cancer
    Chinthalapally V. Rao, Naveena B. Janakiram and Altaf Mohammed
    Clin Cancer Res March 15 2017 23 (6) 1373-1378; DOI:10.1158/1078-0432.CCR-16-0862

Review

  • Review
    Therapeutic Small Molecules Target Inhibitor of Apoptosis Proteins in Cancers with Deregulation of Extrinsic and Intrinsic Cell Death Pathways
    Adeeb Derakhshan, Zhong Chen and Carter Van Waes
    Clin Cancer Res March 15 2017 23 (6) 1379-1387; DOI:10.1158/1078-0432.CCR-16-2172

Cancer Therapy: Clinical

  • Cancer Therapy: Clinical
    Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells
    Chad Tang, James W. Welsh, Patricia de Groot, Erminia Massarelli, Joe Y. Chang, Kenneth R. Hess, Sreyashi Basu, Michael A. Curran, Maria E. Cabanillas, Vivek Subbiah, Siqing Fu, Apostolia M. Tsimberidou, Daniel Karp, Daniel R. Gomez, Adi Diab, Ritsuko Komaki, John V. Heymach, Padmanee Sharma, Aung Naing and David S. Hong
    Clin Cancer Res March 15 2017 23 (6) 1388-1396; DOI:10.1158/1078-0432.CCR-16-1432

  • Cancer Therapy: Clinical
    Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer
    Jung-Min Lee, Cody J. Peer, Minshu Yu, Lauren Amable, Nicolas Gordon, Christina M. Annunziata, Nicole Houston, Andrew K.L. Goey, Tristan M. Sissung, Bernard Parker, Lori Minasian, Victoria L. Chiou, Robert F. Murphy, Brigitte C. Widemann, William D. Figg and Elise C. Kohn
    Clin Cancer Res March 15 2017 23 (6) 1397-1406; DOI:10.1158/1078-0432.CCR-16-1546

  • Cancer Therapy: Clinical
    Modifying the Clinical Research Infrastructure at a Dedicated Clinical Trials Unit: Assessment of Trial Development, Activation, and Participant Accrual
    Chad Tang, Kenneth R. Hess, Dwana Sanders, Suzanne E. Davis, Aman U. Buzdar, Razelle Kurzrock, J. Jack Lee, Funda Meric-Bernstam and David S. Hong
    Clin Cancer Res March 15 2017 23 (6) 1407-1413; DOI:10.1158/1078-0432.CCR-16-1936

  • Cancer Therapy: Clinical
    Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement
    Chad Tang, Steven I. Sherman, Mellanie Price, Jun Weng, Suzanne E. Davis, David S. Hong, James C. Yao, Aman Buzdar, George Wilding and J. Jack Lee
    Clin Cancer Res March 15 2017 23 (6) 1414-1421; DOI:10.1158/1078-0432.CCR-16-2439

Personalized Medicine and Imaging

  • Personalized Medicine and Imaging
    Serum Metabolomic Profiles Identify ER-Positive Early Breast Cancer Patients at Increased Risk of Disease Recurrence in a Multicenter Population
    Christopher D. Hart, Alessia Vignoli, Leonardo Tenori, Gemma Leonora Uy, Ta Van To, Clement Adebamowo, Syed Mozammel Hossain, Laura Biganzoli, Emanuela Risi, Richard R. Love, Claudio Luchinat and Angelo Di Leo
    Clin Cancer Res March 15 2017 23 (6) 1422-1431; DOI:10.1158/1078-0432.CCR-16-1153

  • Personalized Medicine and Imaging | AuthorChoice
    18F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial
    Miguel Quintela-Fandino, Ana Lluch, Luis Manso, Isabel Calvo, Javier Cortes, José Angel García-Saenz, Miguel Gil-Gil, Noelia Martinez-Jánez, Antonio Gonzalez-Martin, Encarna Adrover, Raquel de Andres, Gemma Viñas, Antonio Llombart-Cussac, Emilio Alba, Juan Guerra, Begoña Bermejo, Esther Zamora, Fernando Moreno-Anton, Sonia Pernas Simon, Alfredo Carrato, Antonio Lopez-Alonso, María José Escudero, Ruth Campo, Eva Carrasco, José Palacios, Francisca Mulero and Ramon Colomer
    Clin Cancer Res March 15 2017 23 (6) 1432-1441; DOI:10.1158/1078-0432.CCR-16-0738

  • Personalized Medicine and Imaging
    Radiological Image Traits Predictive of Cancer Status in Pulmonary Nodules
    Ying Liu, Yoganand Balagurunathan, Thomas Atwater, Sanja Antic, Qian Li, Ronald C. Walker, Gary T. Smith, Pierre P. Massion, Matthew B. Schabath and Robert J. Gillies
    Clin Cancer Res March 15 2017 23 (6) 1442-1449; DOI:10.1158/1078-0432.CCR-15-3102

  • Personalized Medicine and Imaging
    Identification of Keratin 19–Positive Cancer Stem Cells Associating Human Hepatocellular Carcinoma Using 18F-Fluorodeoxyglucose Positron Emission Tomography
    Takayuki Kawai, Kentaro Yasuchika, Satoru Seo, Tatsuya Higashi, Takamichi Ishii, Yuya Miyauchi, Hidenobu Kojima, Ryoya Yamaoka, Hokahiro Katayama, Elena Yukie Yoshitoshi, Satoshi Ogiso, Sadahiko Kita, Katsutaro Yasuda, Ken Fukumitsu, Yuji Nakamoto, Etsuro Hatano and Shinji Uemoto
    Clin Cancer Res March 15 2017 23 (6) 1450-1460; DOI:10.1158/1078-0432.CCR-16-0871

  • Personalized Medicine and Imaging
    Co-clinical Assessment of Tumor Cellularity in Pancreatic Cancer
    Irina Heid, Katja Steiger, Marija Trajkovic-Arsic, Marcus Settles, Manuela R. Eßwein, Mert Erkan, Jörg Kleeff, Carsten Jäger, Helmut Friess, Bernhard Haller, Andreas Steingötter, Roland M. Schmid, Markus Schwaiger, Ernst J. Rummeny, Irene Esposito, Jens T. Siveke and Rickmer F. Braren
    Clin Cancer Res March 15 2017 23 (6) 1461-1470; DOI:10.1158/1078-0432.CCR-15-2432

  • Personalized Medicine and Imaging | AuthorChoice
    Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors
    Roz Brant, Alan Sharpe, Tom Liptrot, Jonathan R. Dry, Elizabeth A. Harrington, J. Carl Barrett, Nicky Whalley, Christopher Womack, Paul Smith and Darren R. Hodgson
    Clin Cancer Res March 15 2017 23 (6) 1471-1480; DOI:10.1158/1078-0432.CCR-16-0021

Cancer Therapy: Preclinical

  • Cancer Therapy: Preclinical
    UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models
    Deborah DeRyckere, Alisa B. Lee-Sherick, Madeline G. Huey, Amanda A. Hill, Jeffrey W. Tyner, Kristen M. Jacobsen, Lauren S. Page, Gregory G. Kirkpatrick, Fatma Eryildiz, Stephanie A. Montgomery, Weihe Zhang, Xiaodong Wang, Stephen V. Frye, H. Shelton Earp and Douglas K. Graham
    Clin Cancer Res March 15 2017 23 (6) 1481-1492; DOI:10.1158/1078-0432.CCR-16-1330

  • Cancer Therapy: Preclinical
    The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia–Microenvironment Interactions in Chronic Lymphocytic Leukemia
    Alba Matas-Céspedes, Anna Vidal-Crespo, Vanina Rodriguez, Neus Villamor, Julio Delgado, Eva Giné, Heleia Roca-Ho, Pablo Menéndez, Elías Campo, Armando López-Guillermo, Dolors Colomer, Gaël Roué, Adrian Wiestner, Paul W.H.I. Parren, Parul Doshi, Jeroen Lammerts van Bueren and Patricia Pérez-Galán
    Clin Cancer Res March 15 2017 23 (6) 1493-1505; DOI:10.1158/1078-0432.CCR-15-2095

  • Cancer Therapy: Preclinical | AuthorChoice
    MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies
    Liqin Liu, Chia-Ying K. Lam, Vatana Long, Lusiana Widjaja, Yinhua Yang, Hua Li, Linda Jin, Steve Burke, Sergey Gorlatov, Jennifer Brown, Ralph Alderson, Margaret D. Lewis, Jeffrey L. Nordstrom, Scott Koenig, Paul A. Moore, Syd Johnson and Ezio Bonvini
    Clin Cancer Res March 15 2017 23 (6) 1506-1518; DOI:10.1158/1078-0432.CCR-16-0666

  • Cancer Therapy: Preclinical | AuthorChoice
    Safe and Effective Treatment of Experimental Neuroblastoma and Glioblastoma Using Systemically Delivered Triple MicroRNA-Detargeted Oncolytic Semliki Forest Virus
    Mohanraj Ramachandran, Di Yu, Matheus Dyczynski, Sathishkumar Baskaran, Lei Zhang, Aleksei Lulla, Valeria Lulla, Sirle Saul, Sven Nelander, Anna Dimberg, Andres Merits, Justyna Leja-Jarblad and Magnus Essand
    Clin Cancer Res March 15 2017 23 (6) 1519-1530; DOI:10.1158/1078-0432.CCR-16-0925

  • Cancer Therapy: Preclinical
    AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non–Small Cell Lung Cancer Cells Following EGFR Inhibition
    Hannah A. Scarborough, Barbara A. Helfrich, Matias Casás-Selves, Alwin G. Schuller, Shaun E. Grosskurth, Jihye Kim, Aik-Choon Tan, Daniel C. Chan, Zhiyong Zhang, Vadym Zaberezhnyy, Paul A. Bunn and James DeGregori
    Clin Cancer Res March 15 2017 23 (6) 1531-1541; DOI:10.1158/1078-0432.CCR-16-1179

  • Cancer Therapy: Preclinical
    BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer
    Iris Sze Ue Luk, Raunak Shrestha, Hui Xue, Yuwei Wang, Fang Zhang, Dong Lin, Anne Haegert, Rebecca Wu, Xin Dong, Colin C. Collins, Amina Zoubeidi, Martin E. Gleave, Peter W. Gout and Yuzhuo Wang
    Clin Cancer Res March 15 2017 23 (6) 1542-1551; DOI:10.1158/1078-0432.CCR-16-0718

  • Cancer Therapy: Preclinical | AuthorChoice
    Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer
    Ying Chen, Sandra Catalina Camacho, Thomas R. Silvers, Albiruni R.A. Razak, Nashat Y. Gabrail, John F. Gerecitano, Eva Kalir, Elena Pereira, Brad R. Evans, Susan J. Ramus, Fei Huang, Nolan Priedigkeit, Estefania Rodriguez, Michael Donovan, Faisal Khan, Tamara Kalir, Robert Sebra, Andrew Uzilov, Rong Chen, Rileen Sinha, Richard Halpert, Jean-Noel Billaud, Sharon Shacham, Dilara McCauley, Yosef Landesman, Tami Rashal, Michael Kauffman, Mansoor R. Mirza, Morten Mau-Sørensen, Peter Dottino and John A. Martignetti
    Clin Cancer Res March 15 2017 23 (6) 1552-1563; DOI:10.1158/1078-0432.CCR-16-1333

  • Cancer Therapy: Preclinical
    Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient–Derived Xenografts and Mesothelin as a Biomarker of Tumor Response
    Jingli Zhang, Swati Khanna, Qun Jiang, Christine Alewine, Markku Miettinen, Ira Pastan and Raffit Hassan
    Clin Cancer Res March 15 2017 23 (6) 1564-1574; DOI:10.1158/1078-0432.CCR-16-1667

Biology of Human Tumors

  • Biology of Human Tumors | AuthorChoice
    Interleukin-17–Producing Neutrophils Link Inflammatory Stimuli to Disease Progression by Promoting Angiogenesis in Gastric Cancer
    Tuan-Jie Li, Yu-Ming Jiang, Yan-Feng Hu, Lei Huang, Jiang Yu, Li-Ying Zhao, Hai-Jun Deng, Ting-Yu Mou, Hao Liu, Yang Yang, Qi Zhang and Guo-Xin Li
    Clin Cancer Res March 15 2017 23 (6) 1575-1585; DOI:10.1158/1078-0432.CCR-16-0617

  • Biology of Human Tumors
    Characterization of Biomarkers of Tumorigenic and Chemoresistant Cancer Stem Cells in Human Gastric Carcinoma
    Phu Hung Nguyen, Julie Giraud, Lucie Chambonnier, Pierre Dubus, Linda Wittkop, Geneviève Belleannée, Denis Collet, Isabelle Soubeyran, Serge Evrard, Benoit Rousseau, Nathalie Senant-Dugot, Francis Mégraud, Frédéric Mazurier and Christine Varon
    Clin Cancer Res March 15 2017 23 (6) 1586-1597; DOI:10.1158/1078-0432.CCR-15-2157

  • Biology of Human Tumors
    Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival
    Joo Young Kim, Jacqueline A. Brosnan-Cashman, Soyeon An, Sung Joo Kim, Ki-Byung Song, Min-Sun Kim, Mi-Ju Kim, Dae Wook Hwang, Alan K. Meeker, Eunsil Yu, Song Cheol Kim, Ralph H. Hruban, Christopher M. Heaphy and Seung-Mo Hong
    Clin Cancer Res March 15 2017 23 (6) 1598-1606; DOI:10.1158/1078-0432.CCR-16-1147

  • Biology of Human Tumors | AuthorChoice
    Mutant p53 Together with TGFβ Signaling Influence Organ-Specific Hematogenous Colonization Patterns of Pancreatic Cancer
    Yi Zhong, Anne Macgregor-Das, Tyler Saunders, Martin C. Whittle, Alvin Makohon-Moore, Zachary A. Kohutek, Justin Poling, Brian T. Herbst, Breanna M. Javier, Leslie Cope, Steven D. Leach, Sunil R. Hingorani and Christine A. Iacobuzio-Donahue
    Clin Cancer Res March 15 2017 23 (6) 1607-1620; DOI:10.1158/1078-0432.CCR-15-1615

Back to top
PreviousNext
Clinical Cancer Research: 23 (6)
March 2017
Volume 23, Issue 6
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Editorial Board (PDF)

Sign up for alerts

Issue Highlights

  • Serum Metabolomic Profiles Identify ER-Positive Early Breast Cancer Patients at Increased Risk of Disease Recurrence in a Multicenter Population
  • UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models
  • The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia–Microenvironment Interactions in Chronic Lymphocytic Leukemia
  • Interleukin-17–Producing Neutrophils Link Inflammatory Stimuli to Disease Progression by Promoting Angiogenesis in Gastric Cancer

Jump to

  • Highlights
  • CCR Translations
  • CCR Perspectives in Regulatory Science and Policy
  • Molecular Pathways
  • Review
  • Cancer Therapy: Clinical
  • Personalized Medicine and Imaging
  • Cancer Therapy: Preclinical
  • Biology of Human Tumors
Advertisement
  • Most Cited
  • Most Read
Loading
  • Hyperprogressive Disease with Anti-PD-1/PD-L1 Therapy
  • Multiplex Genome Editing to Generate Universal CAR T Cells
  • Integrated Safety Analysis of Urelumab
  • Genomics of Immunotherapy-Associated Hyperprogressors
  • Translational Genomics in Breast Cancer
More...
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement